StockData
Vaccinex, Inc. logo

Vaccinex, Inc. (VCNX) stock

VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)

Close on Oct 19, 2026Market cap $3.22MP/E –Yield –

Vaccinex operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vaccinex's operating income for the twelve months ending Dec 31, 2024 was -$18.74M. For fiscal 2024 it was -$18.74M. The highest annual figure on record is -$18.74M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$18.74M–
FY2023Dec 31, 2023-$22.89M–
FY2022Dec 31, 2022-$19.91M–
FY2021Dec 31, 2021-$22.49M–
FY2020Dec 31, 2020-$28.33M–
FY2019Dec 31, 2019-$32.02M–
FY2018Dec 31, 2018-$27.28M–
FY2017Dec 31, 2017-$21.10M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$3.39M–
Q3 FY2024Sep 30, 2024-$4.55M–
Q2 FY2024Jun 30, 2024-$5.72M–
Q1 FY2024Mar 31, 2024-$5.07M–
Q4 FY2023Dec 31, 2023-$4.99M–
Q3 FY2023Sep 30, 2023-$5.83M–
Q2 FY2023Jun 30, 2023-$7.08M–
Q1 FY2023Mar 31, 2023-$4.99M–
Q4 FY2022Dec 31, 2022-$5.12M–
Q3 FY2022Sep 30, 2022-$4.79M–
Q2 FY2022Jun 30, 2022-$5.40M–
Q1 FY2022Mar 31, 2022-$4.59M–
Q4 FY2021Dec 31, 2021-$5.52M–
Q3 FY2021Sep 30, 2021-$5.06M–
Q2 FY2021Jun 30, 2021-$5.67M–
Q1 FY2021Mar 31, 2021-$6.24M–
Q4 FY2020Dec 31, 2020-$6.09M–
Q3 FY2020Sep 30, 2020-$8.58M–
Q2 FY2020Jun 30, 2020-$6.50M–
Q1 FY2020Mar 31, 2020-$7.16M–
Q4 FY2019Dec 31, 2019-$6.34M–
Q3 FY2019Sep 30, 2019-$7.68M–
Q2 FY2019Jun 30, 2019-$8.86M–
Q1 FY2019Mar 31, 2019-$9.14M–
Q4 FY2018Dec 31, 2018-$8.56M–
Q3 FY2018Sep 30, 2018-$6.45M–
Q2 FY2018Jun 30, 2018-$6.56M–
Q1 FY2018Mar 31, 2018-$5.71M–
Q4 FY2017Dec 31, 2017-$6.20M–
Q3 FY2017Sep 30, 2017-$5.33M–
Q2 FY2017Jun 30, 2017-$4.67M–

More Vaccinex figures

See a number that looks wrong?